Le Lézard
Classified in: Health, Science and technology

eLife Selects Dimensions to Gather More Advanced Insights


LONDON, Feb. 20, 2019 /PRNewswire-PRWeb/ -- eLife and Digital Science announce an agreement that will see Dimensions rolled out across the organization. Dimensions provides in-depth data, visualizations, and analytics to help publishers make more informed data-driven decisions across their business, support strategic planning, and understand past and future funding activity.

Developed in collaboration with the research community, Dimensions provides researchers with a powerful discovery tool that makes the world of published scholarly literature more discoverable and contextualized. Automatically linked to related grants, patents, clinical trials, policy documents and metrics, Dimensions pulls together information from across the research lifecycle and provides a powerful tool that publishers can use to discover peer reviewers, find authors, and assess the broader impact of their publications. This data also highlights where content has the most value and demand around the world.

Speaking about the adoption of Dimensions, eLife Journal Development Editor Maria Guerreiro commented, "We are very excited to be working with Dimensions. It's a powerful and intuitive system that will allow us a better understanding of the scholarly communication landscape ? specifically how funding, scientists, publications and other research outputs are interconnected. The granular information it provides at the article level is a big plus for us, and very much supports our mission of encouraging more meaningful approaches for research assessment. Moreover, it builds on the open citation data that's been released by many publishers, including eLife, as part of the Initiative for Open Citations."

Christian Herzog, CEO of the Data and Analytics group at Digital Science, adds, "eLife's mission to improve all aspects of research communication in support of excellence in science aligns very closely with our goals in creating Dimensions and we look forward to working with them. "

About eLife
eLife is a non-profit organization inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours in science. We publish work of the highest scientific standards and importance in all areas of the life and biomedical sciences. The research is selected and evaluated by working scientists and is made freely available to all readers without delay. eLife also invests in innovation through open-source tool development to accelerate research communication and discovery. Our work is guided by the communities we serve. Learn more at elifesciences.org/about.

About Dimensions
Dimensions is a modern, innovative, linked research knowledge system that re-imagines discovery and access to research. Developed by Digital Science in collaboration with over 100 leading research organizations around the world, Dimensions brings together grants, publications, citations, alternative metrics, clinical trials and patents to deliver a platform that enables users to find and access the most relevant information faster, analyze the academic and broader outcomes of research, and gather insights to inform future strategy. Visit Dimensions' website at https://dimensions.ai and find us on Twitter @DSDimensions.

About Digital Science
Digital Science is a technology company working to make research more efficient. We invest in, nurture and support innovative businesses and technologies that make all parts of the research process more open and effective. We believe that together, we can help researchers make a difference. Visit http://www.digital-science.com for more information.

 

SOURCE Dimensions


These press releases may also interest you

at 22:15
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

at 21:59
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...



News published on and distributed by: